Silence Therapeutics (SLN) Receivables Refunds (2019 - 2025)
Silence Therapeutics (SLN) has disclosed Receivables Refunds for 7 consecutive years, with $2.6 million as the latest value for Q4 2025.
- Quarterly Receivables Refunds rose 69.29% to $2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2025, up 69.29% year-over-year, with the annual reading at $2.6 million for FY2025, 69.29% up from the prior year.
- Receivables Refunds hit $2.6 million in Q4 2025 for Silence Therapeutics, up from $1.5 million in the prior quarter.
- In the past five years, Receivables Refunds ranged from a high of $21.9 million in Q4 2023 to a low of $1.5 million in Q4 2024.
- Historically, Receivables Refunds has averaged $10.6 million across 5 years, with a median of $9.4 million in 2021.
- Biggest five-year swings in Receivables Refunds: surged 100.28% in 2021 and later plummeted 92.96% in 2024.
- Year by year, Receivables Refunds stood at $9.4 million in 2021, then skyrocketed by 86.45% to $17.5 million in 2022, then rose by 25.33% to $21.9 million in 2023, then tumbled by 92.96% to $1.5 million in 2024, then skyrocketed by 69.29% to $2.6 million in 2025.
- Business Quant data shows Receivables Refunds for SLN at $2.6 million in Q4 2025, $1.5 million in Q4 2024, and $21.9 million in Q4 2023.